Fig 1: Flow cytometry analysis of monocytes in cryopreserved PBMC from patient 6 h post-OHCACryopreserved PBMC from patients 6 h post-CA or control subjects (“Healthy”) were analyzed by flow cytometry using the methods described in our companion paper by Tamura, Cheng et al.1 OHCA patients were subdivided by neurological outcomes. Neurological outcome was defined by CPC scores at 30 days post-OHCA, with 1-2 as “Good” or 3–5 as “Poor”. The percentage of CD14+ monocytes expressing CD36 or MerTK are shown. Kruskal-Wallis test, ∗P < 0.05. Data are represented as mean ± SD. MerTK, Mer proto-oncogene tyrosine kinase; OHCA, out-of-hospital cardiac arrest; Healthy, healthy cohort; Good and Poor indicates neurological outcomes after OHCA.